Literature DB >> 28931543

Effects of intravenous low-dose dopamine infusion on glucose regulation during prolonged aerobic exercise.

Blair D Johnson1,2, Ana B Peinado1,3, Sushant M Ranadive1, Timothy B Curry1, Michael J Joyner1.   

Abstract

The carotid body chemoreceptors are activated during hypoglycemia and contribute to glucoregulation during prolonged exercise in dogs. Low-dose intravenous infusions of dopamine have been shown to blunt the activation of the carotid body chemoreceptors during hypoxia. Therefore, we tested the hypotheses that dopamine would blunt glucoregulatory responses and attenuate plasma glucose during prolonged aerobic exercise in healthy participants. Twelve healthy participants completed two randomized exercise sessions at 65% peak oxygen consumption for up to 120 min. Saline was infused during one exercise session, and dopamine (2 μg·kg-1·min-1) was infused during the other session. Arterial plasma glucose, growth hormone, glucagon, cortisol, norepinephrine, and epinephrine were measured every 10 min. Exercise duration during dopamine infusion was 107 ± 6 and 119 ± 0.8 min during saline infusion. Glucose area under the curve during exercise was lower during dopamine (9,821 ± 686 vs. 11,194 ± 395 arbitrary units; P = 0.016). The ratio of circulating growth hormone to glucose and the ratio of glucagon to glucose were greater during dopamine ( P = 0.045 and 0.037, respectively). These results indicate that the infusion of dopamine during aerobic exercise impairs glucoregulation. This suggests that the carotid body chemoreceptors contribute to glucoregulation during prolonged exercise in healthy exercise-trained humans.

Entities:  

Keywords:  cortisol; epinephrine; glucagon; growth hormone; norepinephrine

Mesh:

Substances:

Year:  2017        PMID: 28931543      PMCID: PMC5866361          DOI: 10.1152/ajpregu.00030.2017

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  51 in total

1.  Activation of the carotid chemoreflex secondary to muscle metaboreflex stimulation in men.

Authors:  H Edgell; M K Stickland
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-02-26       Impact factor: 3.619

2.  Species difference in carotid body response of cat and dog to dopamine and serotonin.

Authors:  A M Black; J H Comroe; L Jacobs
Journal:  Am J Physiol       Date:  1972-11

3.  Hyperoxia decreases muscle glycogenolysis, lactate production, and lactate efflux during steady-state exercise.

Authors:  Trent Stellingwerff; Paul J Leblanc; Melanie G Hollidge; George J F Heigenhauser; Lawrence L Spriet
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-01-10       Impact factor: 4.310

4.  Carotid chemoreceptor modulation of blood flow during exercise in healthy humans.

Authors:  Michael K Stickland; Desi P Fuhr; Mark J Haykowsky; Kelvin E Jones; D Ian Paterson; Justin A Ezekowitz; M Sean McMurtry
Journal:  J Physiol       Date:  2011-10-24       Impact factor: 5.182

Review 5.  The effects of dopamine on the respiratory system: friend or foe?

Authors:  Agnieszka Ciarka; Jean-Louis Vincent; Philippe van de Borne
Journal:  Pulm Pharmacol Ther       Date:  2006-10-27       Impact factor: 3.410

6.  Stimulation of hypoxic ventilatory drive by droperidol.

Authors:  D S Ward
Journal:  Anesth Analg       Date:  1984-02       Impact factor: 5.108

7.  Effects of increased inspired oxygen concentrations on exercise performance in chronic heart failure.

Authors:  D P Moore; A R Weston; J M Hughes; C M Oakley; J G Cleland
Journal:  Lancet       Date:  1992-04-04       Impact factor: 79.321

8.  Dopamine depresses minute ventilation in patients with heart failure.

Authors:  P van de Borne; R Oren; V K Somers
Journal:  Circulation       Date:  1998-07-14       Impact factor: 29.690

9.  Respiratory neuroplasticity following carotid body denervation: Central and peripheral adaptations.

Authors:  Matthew R Hodges; Hubert V Forster
Journal:  Neural Regen Res       Date:  2012-05-15       Impact factor: 5.135

10.  Comparing and characterizing transient and steady-state tests of the peripheral chemoreflex in humans.

Authors:  Jamie R Pfoh; Michael M Tymko; Maria Abrosimova; Lindsey M Boulet; Glen E Foster; Anthony R Bain; Philip N Ainslie; Craig D Steinback; Christina D Bruce; Trevor A Day
Journal:  Exp Physiol       Date:  2016-03       Impact factor: 2.969

View more
  6 in total

Review 1.  Role of the carotid body chemoreceptors in glucose homeostasis and thermoregulation in humans.

Authors:  Michael J Joyner; Jacqueline K Limberg; Erica A Wehrwein; Blair D Johnson
Journal:  J Physiol       Date:  2018-03-05       Impact factor: 5.182

Review 2.  Glucose, insulin, and the carotid body chemoreceptors in humans.

Authors:  Jacqueline K Limberg
Journal:  Physiol Genomics       Date:  2018-04-13       Impact factor: 3.107

3.  Carotid body chemosensitivity at 1.6 ATA breathing air versus 100% oxygen.

Authors:  Hayden W Hess; David Hostler; Brian M Clemency; Blair D Johnson
Journal:  J Appl Physiol (1985)       Date:  2020-06-25

Review 4.  Assessment of resistance vessel function in human skeletal muscle: guidelines for experimental design, Doppler ultrasound, and pharmacology.

Authors:  Jacqueline K Limberg; Darren P Casey; Joel D Trinity; Wayne T Nicholson; D Walter Wray; Michael E Tschakovsky; Daniel J Green; Ylva Hellsten; Paul J Fadel; Michael J Joyner; Jaume Padilla
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-12-30       Impact factor: 4.733

Review 5.  G-Protein-Coupled Receptor (GPCR) Signaling in the Carotid Body: Roles in Hypoxia and Cardiovascular and Respiratory Disease.

Authors:  Hayyaf S Aldossary; Abdulaziz A Alzahrani; Demitris Nathanael; Eyas A Alhuthail; Clare J Ray; Nikolaos Batis; Prem Kumar; Andrew M Coney; Andrew P Holmes
Journal:  Int J Mol Sci       Date:  2020-08-20       Impact factor: 5.923

Review 6.  Carotid Body and Metabolic Syndrome: Mechanisms and Potential Therapeutic Targets.

Authors:  Lenise J Kim; Vsevolod Y Polotsky
Journal:  Int J Mol Sci       Date:  2020-07-20       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.